
    
      This multicenter, randomized, placebo-controlled, double-blind study is designed to
      demonstrate the efficacy, safety and tolerability of pradigastat relative to placebo across 2
      doses (20 and 40 mg) for up to 6 weeks (4-week treatment, 2-week Follow-up) in patients with
      Functional Constipation.

      The primary endpoint is the change from baseline in the number of weekly spontaneous bowel
      movement (SBM), the key secondary endpoint is the change from baseline in the number of
      weekly complete spontaneous bowel movement (CSBM).An SBM is defined as a stool not induced by
      rescue medication, whereas a CSBM is defined as an SBM associated with a sensation of
      complete evacuation.
    
  